Loading organizations...
§ Private Profile · Fremont, CA, USA
Biopharmaceutical company developing monoclonal antibody therapeutics using XenoMouse technology for cancer, inflammation, and infectious diseases.
Key people at Abgenix.
Abgenix was a Fremont, California-based biopharmaceutical company that developed monoclonal antibody therapeutics using its proprietary XenoMouse technology to produce fully human antibodies for oncology, inflammation, and infectious diseases. The firm generated revenue by licensing its transgenic mouse platform and co-developing proprietary therapeutics through strategic partnerships with major pharmaceutical corporations, including Amgen, Bristol-Myers Squibb, and Merck. Originally funded by a $1 million initial investment, the enterprise operated as a publicly traded entity and acquired cancer immunotherapy firm Antigenics in 2003. The business ultimately achieved a $2.2 billion cash and debt assumption acquisition by Amgen in April 2006. Prior to this exit, the company co-developed the colorectal cancer drug Vectibix, which later received FDA approval. Abgenix was founded as a spin-off from Cell Genesys in 1995 by Raymond Withy, Robert Tepper, Scott Greer, and Raju Kucherlapati.
Key people at Abgenix.
Abgenix was a biopharmaceutical company focused on discovering, developing, and manufacturing fully human monoclonal antibodies for treating diseases like cancer, inflammation, and infectious conditions.[1][2][3] Its core technology, XenoMouse, enabled production of human antibodies by engineering mice with human antibody genes, addressing unmet needs in therapeutics such as ABX-EGF (later Vectibix/panitumumab) for cancer.[1][2] The company served pharmaceutical partners like Amgen, Bristol-Myers Squibb, and Merck through collaborations, raised $246.64M, and grew to 250-500 employees before being acquired by Amgen in 2006 for full ownership of key assets like panitumumab and to eliminate royalties on denosumab.[2][3][4]
Founded in 1995 (or 1996 per some records) in Fremont, California, Abgenix started with four entrepreneurs—Scott Greer, Raju Kucherlapati, Raymond Withy, and Robert Tepper—who bootstrapped it with $1 million of personal funds.[1][2][3] The idea emerged from advancing monoclonal antibody technology, specifically creating the XenoMouse strain to produce fully human antibodies, reducing immunogenicity issues in therapies.[1] Early traction included partnerships with major biopharma firms, first clinical trials of ABX-EGF in 2001, acquisition of Antigenics in 2003, and FDA approval of Vectibix in 2005 via Amgen collaboration, culminating in Amgen's full acquisition in April 2006.[1][4]
Abgenix rode the late-1990s biotech boom in antibody therapeutics, capitalizing on genomics and genetic engineering to solve immunogenicity challenges in monoclonal antibodies—a market force shifting from murine to fully human therapies.[1][3] Timing was ideal amid rising demand for targeted cancer treatments, with XenoMouse enabling faster, safer drug discovery amid the Human Genome Project's influence.[1][2] It influenced the ecosystem by validating antibody platforms (e.g., panitumumab's approval advanced colorectal cancer care) and through Amgen's 2006 acquisition, consolidating expertise to scale production for millions of patients, boosting oncology biopharma confidence.[4]
Abgenix's legacy endures through Amgen's portfolio: panitumumab (Vectibix) remains a standard in oncology, while denosumab royalties were eliminated, freeing resources for broader innovation.[4] Post-acquisition, its XenoMouse tech integrated into Amgen's operations, contributing to supportive care for over six million cancer patients.[4] Looking ahead, trends like antibody-drug conjugates and next-gen immunotherapies (echoed in successors like Oxford BioTherapeutics) build on Abgenix's foundation, with its Fremont HQ and patents shaping modern biopharma's push for humanized therapies against resistant cancers and pandemics.[2][3] As a pioneer, Abgenix exemplified how bootstrapped biotech can redefine antibody discovery, paving Amgen's path to global leadership.
